Atrium Therapeutics develops precision RNA therapeutics designed for targeted delivery directly to heart muscle tissue to treat genetic forms of cardiomyopathy. Its platform leverages antibody-oligonucleotide conjugate technology to address previously challenging cardiac indications, with lead programs focused on PRKAG2 syndrome and PLN cardiomyopathy. The company aims to transform care for patients with rare and genetically driven heart diseases through selective RNA medicines.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 3 | — | -46.2 | — |
| Q1 2025 | 1.6 | — | -7.5 | — |
| Q4 2025 | 0.9 | -71.1% | -48.1 | — |
| Q1 2026 | 19.6 | 1,148.3% | -16.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Crown Reserve Acquisition Corp. I (CRAC), FB Bancorp, Inc. (FBLA), XChange TEC.INC (XHG), AstroNova, Inc. (ALOT), Mercator Acquisition Corp. (MRCO), Jin Medical International Ltd. (ZJYL)